Neuronal Cannabinoid CB1 Receptors Suppress the Growth of Melanoma Brain Metastases by Inhibiting Glutamatergic Signalling
Authors:
- Carlos Costas-InsuaCCCarlos Costas-Insua
- Marta Seijo-VilaMSMarta Seijo-Vila
- Cristina BlázquezCBCristina Blázquez
- Sandra Blasco-BenitoSBSandra Blasco-Benito
- Francisco Javier Rodríguez-BaenaFRFrancisco Javier Rodríguez-Baena
- Giovanni MarsicanoGMGiovanni Marsicano
- Eduardo Pérez-GómezEPEduardo Pérez-Gómez
- Cristina SánchezCSCristina Sánchez
- Berta Sánchez-LaordenBSBerta Sánchez-Laorden
- Manuel GuzmánMGManuel Guzmán
Open Access
Abstract
Melanoma is one of the deadliest forms of cancer. Most melanoma deaths are caused by distant metastases in several organs, especially the brain, the so-called melanoma brain metastases (MBMs). However, the precise mechanisms that sustain the growth of MBMs remain elusive. Recently, the excitatory neurotransmitter glutamate has been proposed as a brain-specific, pro-tumorigenic signal for various types of cancers, but how neuronal glutamate shuttling onto metastases is regulated remains unknown. Here, we show that the cannabinoid CB1 receptor (CB1R), a master regulator of glutamate output from nerve terminals, controls MBM proliferation. First, in silico transcriptomic analysis of cancer-genome atlases indicated an aberrant expression of glutamate receptors in human metastatic melanoma samples. Second, in vitro experiments conducted on three different melanoma cell lines showed that the selective blockade of glutamatergic NMDA receptors, but not AMPA or metabotropic receptors, reduces cell proliferation. Third, in vivo grafting of melanoma cells in the brain of mice selectively devoid of CB1Rs in glutamatergic neurons increased tumour cell proliferation in concert with NMDA receptor activation, whereas melanoma cell growth in other tissue locations was not affected. Taken together, our findings demonstrate an unprecedented regulatory role of neuronal CB1Rs in the MBM tumour microenvironment.Keywords
Funding Information
- Spanish Ministerio de Ciencia e Innovación (PID2021-125118OB-I00, PID2019-106852RB-I00, PI17/00041, PI20/00590, 2023/0036, FPU16/02593)
- Fundación Canna (PID2021-125118OB-I00, PID2019-106852RB-I00, PI17/00041, PI20/00590, 2023/0036, FPU16/02593)
- Inserm (PID2021-125118OB-I00, PID2019-106852RB-I00, PI17/00041, PI20/00590, 2023/0036, FPU16/02593)
- Spanish Ministerio de Universidades (PID2021-125118OB-I00, PID2019-106852RB-I00, PI17/00041, PI20/00590, 2023/0036, FPU16/02593)
- Universidad Complutense de Madrid (PID2021-125118OB-I00, PID2019-106852RB-I00, PI17/00041, PI20/00590, 2023/0036, FPU16/02593)
This publication has 65 references indexed in Scilit:
- Blocking glutamate‐mediated signalling inhibits human melanoma growth and migrationExperimental Dermatology, 2012
- Exome sequencing identifies GRIN2A as frequently mutated in melanomaNature Genetics, 2011
- Determinants of survival in patients with brain metastases from cutaneous melanomaBritish Journal of Cancer, 2010
- Brain metastases admissions in Sweden between 1987 and 2006British Journal of Cancer, 2009
- CB2receptors in the brain: role in central immune functionBritish Journal of Pharmacology, 2008
- Genetic Dissection of Behavioural and Autonomic Effects of Δ9-Tetrahydrocannabinol in MicePLOS Biology, 2007
- Autocrine Glutamate Signaling Promotes Glioma Cell InvasionCancer Research, 2007
- The Endocannabinoid System Controls Key Epileptogenic Circuits in the HippocampusNeuron, 2006
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptorsNeuropharmacology, 1998